Segment and Geographic Area Information (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Segment Information

Schedule of consolidated financial information by segment

	Three months ended March 31,
(in millions)	2013	2012
HUMIRA	$2,244	$1,934
Synagis	345	346
AndroGel	240	232
Kaletra	219	221
Niaspan	186	191
Lupron	181	199
Sevoflurane	137	156
TriCor/TRILIPIX	128	254
Synthroid	119	129
Creon	90	68
Norvir	82	83
Zemplar	81	90
All other	277	270
Net sales	$4,329	$4,173

years ended December 31 (in millions)	2012		2011		2010
HUMIRA	$	9,265	$	7,932	$	6,508
AndroGel		1,152		874		649
TriCor/TRILIPIX		1,098		1,372		1,355
Kaletra		1,013		1,170		1,223
Niaspan		911		976		927
Synagis		842		792		726
Lupron		800		810		741
Sevoflurane		602		665		664
Synthroid		551		522		451
Norvir		389		419		344
Zemplar		383		409		596
Creon		353		332		246
All other		1,021		1,171		1,208
Net sales	$	18,380	$	17,444	$	15,638

Schedule of sales by geographic area

years ended December 31 (in millions)	2012		2011		2010
United States	$	10,435	$	9,712	$	8,971
The Netherlands		776		904		845
Germany		756		701		635
Japan		718		616		484
United Kingdom		552		496		418
Spain		525		569		515
France		500		516		479
Canada		500		446		374
Brazil		434		382		287
Italy		408		428		385
All other countries		2,776		2,674		2,245
Net sales	$	18,380	$	17,444	$	15,638